Multiple Myeloma Genome Unlocked
Discovery paves way for better therapies for some blood cancer patients, experts say
WEDNESDAY, July 29 (HealthDay News) -- The sequencing of the first three multiple myeloma
whole genomes has been completed by U.S. scientists, who said this success will lead to a better understanding ...
CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs
NEW YORK, July 20 /PRNewswire/ -- Cancer Care announced today the launch of the "Door to Door" program for patients with multiple myeloma. Cancer Care 's program will provide individual grants of up to $600 annually to multiple myeloma
patients for covering transportation cost...
New Report Just Published: World Multiple Myeloma Therapeutics Market Report
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Multiple Myeloma
MMRF and the Broad Institute to perform whole genome sequencing of multiple myeloma samples
The Multiple Myeloma
Research Foundation (MMRF) announced today a collaboration with the Broad Institute of MIT and Harvard to systematically uncover the molecular changes underlying multiple myeloma
by whole genome sequencing of individual patient tumors. The MMRF will provide both patient sample...
Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
CAMBRIDGE, Mass., Feb. 23 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced that 100 data presentations on VELCADE research will be featured at the Fifth International Myeloma
Workshop (IMW) in Washington, D.C., February 26 - March 1, 2009. The 13 oral and 87 poster presenta...
International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease
LOS ANGELES, Feb. 23 /PRNewswire-USNewswire/ -- On Wednesday, February 25, 2009, the Institute for Myeloma
and Bone Cancer Research (IMBCR) will host a roundtable discussion bringing leading scientists in the field of cancer research together to discuss monoclonal gammopathy of undetermined signif...
Managing Myeloma (www.managingmyeloma.com) Launches - A Comprehensive Information and Educational Site for Physicians, Nurse Practitioners, Physician Assistants, and Pharmacists
MORRISVILLE, Pa., Feb. 12 /PRNewswire/ -- MediCom Worldwide, Inc., an accredited provider of continuing medical education for physicians, pharmacists, and nurses, announces the launch of an online repository of resources and education on the treatment of multiple myeloma
by a multidisciplinary net...
Institute of Myeloma and Bone Cancer Research in Los Angeles Proudly Announces That Ethan Horwitz, Esq of King & Spalding Law Firm has Joined its Board of Directors
LOS ANGELES, Feb. 6 /PRNewswire-USNewswire/ -- Established in 2004, the Institute for Myeloma
and Bone Cancer Research (IMBCR) is the only non-profit, independent cancer research institute focused on creating novel therapies and ultimately a cure for multiple myeloma
and metastatic bone disease.
Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
NEW BRUNSWICK, N.J., Feb. 3 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US : SNT) today announced results of efficacy, toxicological and dose-finding studies in mice for its potential multiple myeloma
drug candidate, SNS-01. SNS-01 is a n...
1.2 Million Dollars Recently Awarded to Institute for Myeloma and Bone Cancer Research
FJC, a foundation of philanthropic donor-advised funds and the Myeloma
Research Foundation are the latest major donors to the "Cure Myeloma
Project", an ongoing research initiative at the Institute for Myeloma
and Bone Cancer Research, (IMBCR), in Los Angeles, CA
LOS ANGELES, Jan. 26 /PRNewsw...
Combo Therapy Helps Multiple Myeloma Patients
Three-quarters of those who had relapsed saw disease stabilize or improve, study shows
FRIDAY, Dec. 12 (HealthDay News) -- A new combination of medicines designed to boost immune function can help some multiple myeloma
patients, according to interim results from an ongoing Mayo Clinic ...
Drug combination improves or stabilizes disease for relapsed multiple myeloma patients
ROCHESTER, Minn. -- Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma
for 76 percent of patients who had relapsed after previous treatment.
Interim results of an ongoing clinical trial evaluati...
Treatment with anti-anemia drugs may not be safe for multiple myeloma patients
Thessaloniki, Greece - August 4, 2008 - A recent study published in American Journal of Hematology demonstrated that Erythropoiesis-stimulating agents (ESAs), a widely used drug to treat anemia, may have a negative impact on the survival of myeloma
patients. In the study, 323 multiple myeloma
How molecules out of balance lead to human multiple myeloma and other cancers
An international team of scientists has identified processes that are heavily implicated in human multiple myeloma
and other B cell cancers, moving us closer to developing quick tests and readouts that could help in the tailored treatment of patients.
B cells, the white blood cells that produce...
Senesco Expands on Preclinical Multiple Myeloma Findings
NEW BRUNSWICK, N.J., June 5 /PRNewswire-FirstCall/ -- Senesco
Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today
further details of its continuing preclinical multiple myeloma
February 2008, the Company announced results of preclinical animal studies
McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute
DETROIT, April 11 /PRNewswire-USNewswire/ -- The McCarty Cancer
Foundation has awarded Jeffrey Zonder, M.D., Assistant Professor of
Medicine and Oncology, Barbara Ann Karmanos Cancer Institute and Wayne
State University School of Medicine, a $50,000 grant for the multi-center
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
-- Trial results of combination therapy VELCADE, melphalan and prednisone
reported a 32 percent complete remission rate with 85 percent of patients alive at three years --
CAMBRIDGE, Mass., March 13 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLN...
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals,
Inc. (Nasdaq: MLNM ) today reported the presentation of results from a 482
patient, multi-center, randomized Phase III clinical trial, comparing
VELCADE and dexamethasone (VcD) to vincristine, adriamycin and
New therapeutic options for newly diagnosed multiple myeloma patients
ATLANTA -- Mayo Clinic researchers today presented results of a phase II trial of myeloma
induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomi...
Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
- Data Demonstrate 17.6 Month Overall Survival Advantage in Elderly Myeloma
Patients when Thalidomide Is Added to Standard Therapy - Data Presented at the 49th American Society of Hematology Meeting
ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq:
PHRM) today anno...
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
- VELCADE based therapy achieved highly significant improvement across all efficacy endpoints including overall survival -
ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals,
Inc. (Nasdaq: MLNM ) today announced the presentation of results from the
682 patient, ran...
Drug Combo Boosts Multiple Myeloma Survival
A thalidomide derivative plus dexamethasone improved outcomes, studies found
WEDNESDAY, Nov. 21 (HealthDay News) -- A combination drug regimen that includes a derivative of thalidomide extended survival, as well as the time it took for the disease to reappear, in patients with multiple...
Studies attribute recent increase in multiple myeloma survival to novel therapies
(WASHINGTON, November 1, 2007) Multiple myeloma
is one of the most common and devastating bone marrow cancers in the U.S., but survival rates have risen dramatically over the past decade. Recent analyses suggest that this trend may be attributed to new types of drugs and aggressive therapeutic in...
Thalidomide Improves Outcomes for Older Myeloma Patients
Adding the drug to standard chemo boosted survival, study found
FRIDAY, Oct. 5 (HealthDay News) -- Elderly patients with multiple myeloma
live longer when thalidomide is added to standard combination chemotherapy treatment, a new study finds.
The finding could be the first real treatment adv...
Gene Test Could Boost Myeloma Treatment
Certain DNA influences who'll respond best to therapy, scientists say
THURSDAY, Sept. 20 (HealthDay News) -- Analyzing the activity of a small subset of genes may help identify patients with the worst cases of multiple myeloma, U.S. researchers say.
It may also help guide their treatment, not...
Gene profiling can single out the worst cases of multiple myeloma and guide therapy
ATLANTA Multiple myeloma
patients vary widely in how they respond to treatment, but now researchers at the Myeloma
Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potenti...
Human C-reactive protein regulates myeloma tumor cell growth and survival
Scientists report that a protein best known as a common marker of inflammation plays a key role in the progression of human cancer. The research, published by Cell Press in the September issue of the journal Cancer Cell, implicates C-reactive protein (CRP) as a potential target for cancer treatmen...
Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathw...
Combination Therapy Helps to Combat Myeloma
Adding Velcade to standard drug therapy prolonged survival, study finds
WEDNESDAY, Aug. 27 (HealthDay News) -- Patients with multiple myeloma
who could not tolerate high dose chemotherapy lived longer and better by adding the drug Velcade to standard treatment, a new study found.
Thalidomide Continues to Show Benefits Against Myeloma
The once-notorious drug aiding certain patients with the blood cancer
WEDNESDAY, July 9 (HealthDay News) -- Researchers exploring the benefits of the once-banned drug thalidomide for patients with myeloma
have learned a lesson that's as true to life as it is to science: Don't judge res...
One Gene May Be Key to Myeloma
The discovery holds promise as a treatment target for this diverse disease, experts say
MONDAY, June 23 (HealthDay News) -- Cancerous myeloma
cells are so "addicted" to a gene known as IRF4, they simply can't live without it, new research has revealed.
Reducing the activity of the g...
FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
- New indication offers earlier treatment options for patients -
CAMBRIDGE, Mass. and OSAKA, Japan, June 20 /PRNewswire/ -- Millennium
Pharmaceuticals, The Takeda Oncology Company, and Takeda Pharmaceutical
Company Limited ("Takeda", TSE: 4502) today announced that the U.S. Food
and Drug A...
Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
Kosan Leads Industry with Most Advanced Hsp90 Inhibitor in Clinical Development
New Supportive Trial in Less Refractory Patients to Replace Current TIME-2 Trial Conference Call and Webcast Today
HAYWARD, Calif., ...
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
CAMBRIDGE, Mass., Dec. 21 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced the submission of a
supplemental new drug application (sNDA) with the U.S. Food and Drug
Administration (FDA) for VELCADE in the treatment of patients with
3-drug combination 'extremely promising' as first-line therapy for multiple myeloma
ATLANTAA new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
- VELCADE, thalidomide and dexamethasone improved pre
- and post-stem cell transplantation results compared to thalidomide and dexamethasone -
ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals,
Inc. (Nasdaq: MLNM ) reported the presenta...
Penn's Abramson Cancer Center part of major phase III study for myeloma
PHILADELPHIA Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow. The...
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
- Underscores Benefit for Patients with Kidney Impairments - - Highlights Leading Role of VELCADE in Broad Range of Patients -
CAMBRIDGE, Mass., Oct. 15 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the U.S. Food and
The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
Free, Interactive Telephone Education Program Features Myeloma
Experts, Melissa Alsina, M.D. and Kathy A. Daily, R.N.
WHITE PLAINS, N.Y., Oct. 4 /PRNewswire/ -- Myeloma
patients can learn
about managing side effects during a free telephone education workshop
sponsored by The Leukem...
Emory researchers identify signaling protein for multiple myeloma
Researchers at Emory Universitys Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma
cell cycle and survival. Their research may result in identification of a new therapeutic target for treating multiple myeloma.
The results of the ...